Advertisement

Iron Chelation

  • Norbert Gattermann
  • Christian Rose
Chapter
Part of the Hematologic Malignancies book series (HEMATOLOGIC)

Abstract

Iron overload in MDS results from increased intestinal iron absorption due to ineffective erythropoiesis and, more importantly, from chronic transfusion therapy. Blood transfusions are necesssary to extend the survival of patients with MDS and improve their quality of life. However, the ensuing transfusional iron overload has a dose dependent negative impact on survival. Cardiac dysfunction appears to be relevant in this context, as a consequence of chronic anemia, age-related cardiac comorbidity, and iron overload. In addition, iron-related endothelial dysfunction and a higher risk of infection should be taken into account. Iron overload may also aggravate the bone marrow failure in MDS. Clinical trials have shown that iron chelators can improve hematopoiesis in a minority of transfusion-dependent patients. Analyses of registry data suggest that iron chelation provides a survival benefit for patients with MDS, but data from a randomized clinical trial are still lacking.

References

  1. 1.
    Santini V, Girelli D, Sanna A, Martinelli N, Duca L, Campostrini N, et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS ONE. 2011;6(8):e23109.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13:1096–101.CrossRefGoogle Scholar
  3. 3.
    Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells of the iron regulatory protein hepcidin. Blood. 2009;114:181–6.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678–84.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Mossner M, Stoehr A, Jann J-C, Nolte F, Nowak V, Oblaender J, et al. Erythroferrone (ERFE) is selectively expressed in human CD71+ erythroprogenitor cells and deregulated overexpression is associated with a favorable outcome in low risk myelodysplastic syndrome (MDS). Blood. 2015;126(23):2859.Google Scholar
  6. 6.
    Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011;96(10):1433–40.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006;91:1588–90.PubMedGoogle Scholar
  8. 8.
    de Swart L, Smith A, Fenaux P, Bowen D, Sanz G, Hellström-Lindberg E, et al. Transfusion-dependency Is the most important prognostic factor for survival in 1000 newly diagnosed MDS patients with low- and intermediate-1 risk MDS in the European LeukemiaNet MDS registry. Blood. 2011;118(21):2775.Google Scholar
  9. 9.
    Roy NB, Myerson S, Schuh AH, Bignell P, Patel R, Wainscoat JS, et al. Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes. Br J Haematol. 2011;154(4):521–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Pascal L, Beyne-Rauzy O, Brechignac S, Marechaux S, Vassilieff D, Ernst O, et al. Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients. Br J Haematol. 2013;162(3):413–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Wood JC, Otto-Duessel M, Aguilar M, Nick H, Nelson MD, Coates TD, et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of cardiomyopathy. Circulation. 2005;112:535–43.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, et al. On T2* magnetic resonance and cardiac iron. Circulation. 2011;123(14):1519–28.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Vinchi F, Muckenthaler MU, Da Silva MC, Balla G, Balla J, Jeney V. Atherogenesis and iron: from epidemiology to cellular level. Front Pharmacol. 2014;5:94.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF Jr, et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation. 2001;103(23):2799–804.CrossRefPubMedGoogle Scholar
  15. 15.
    Cheung YF, Chan GCF, Ha SY. Effect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia major. Br J Haematol. 2008;141:728–33.CrossRefPubMedGoogle Scholar
  16. 16.
    Okabe H, Suzuki T, Uehara E, Ueda M, Nagai T, Ozawa K. The bone marrow hematopoietic microenvironment is impaired in iron-overloaded mice. Eur J Haematol. 2014;93(2):118–28.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhang Y, Zhai W, Zhao M, Li D, Chai X, Cao X, et al. Effects of iron overload on the bone marrow microenvironment in mice. PLoS One. 2015;10(3):e0120219.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Bowen D, Wang L, Frew M, Kerr R, Groves M. Antioxidant enzyme expression in myelodysplastic and acute myeloid leukemia bone marrow: further evidence of a pathogenetic role for oxidative stress? Haematologica. 2003;88:1070–2.PubMedGoogle Scholar
  19. 19.
    Thompson JE, Conlon JP, Yang X, Sanchez PV, Carroll M. Enhanced growth of myelodysplastic colonies in hypoxic conditions. Exp Hematol. 2007;35(1):21–31.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ghoti H, Amer J, Winder A, Rachmilewitz E, Fibach E. Oxidative stress in red blood cells, platelets, and polymorphonuclear leukocytes from patients with myelodysplastic syndromes. Eur J Haematol. 2007;79:463–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Novotna B, Bagryantseva Y, Siskova M, Neuwirtova R. Oxidative damage in bone marrow cells of patients with low-risk myelodysplastic syndrome. Leuk Res. 2009;33:340–3.CrossRefPubMedGoogle Scholar
  22. 22.
    Chung YJ, Robert C, Gough SM, Rassool FV, Aplan PD. Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome. Leuk Res. 2014;38(1):95–102.CrossRefPubMedGoogle Scholar
  23. 23.
    Saigo K, Takenokuchi M, Hiramatsu Y, Tada H, Hishita T, Takata M, et al. Oxidative stress levels in myelodysplastic syndrome patients: their relationship to serum ferritin and haemoglobin values. J Int Med Res. 2011;39(5):1941–5.CrossRefPubMedGoogle Scholar
  24. 24.
    de Souza GF, Barbosa MC, Santos TE, Carvalho TM, de Freitas RM, Martins MR, et al. Increased parameters of oxidative stress and its relation to transfusion iron overload in patients with myelodysplastic syndromes. J Clin Pathol. 2013;66(11):996–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Lu W, Zhao M, Rajbhandary S, Xie F, Chai X, Mu J, et al. Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients. Eur J Haematol. 2013;91(3):249–61.CrossRefPubMedGoogle Scholar
  26. 26.
    Kikuchi S, Kobune M, Iyama S, Sato T, Murase K, Kawano Y, et al. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox. Free Radic Biol Med. 2012;53(4):643–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Hartmann J, Braulke F, Sinzig U, Wulf G, Maas JH, Konietschke F, et al. Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes. Leuk Res. 2013;37(3):327–32.CrossRefPubMedGoogle Scholar
  28. 28.
    Prus E, Fibach E. Uptake of non-transferrin iron by erythroid cells. Anemia. 2011;2011:8.CrossRefGoogle Scholar
  29. 29.
    Taoka K, Kumano K, Nakamura F, Hosoi M, Goyama S, Imai Y, et al. The effect of iron overload and chelation on erythroid differentiation. Int J Hematol. 2012;95(2):149–59.CrossRefPubMedGoogle Scholar
  30. 30.
    Westhofen G, Ganster C, Beier F, Rassaf T, Al-Ali HF, Stuhlmann R, et al. Comprehensive genomic analysis provides further evidence that iron overload can induce genetic instability in myelodysplastic syndromes. Blood. 2015;126(23):2842.Google Scholar
  31. 31.
    List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol. 2012;30(17):2134–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Gattermann N, Finelli C, Della Porta M, Fenaux P, Stadler M, Guerci-Bresler A, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica. 2012;97(9):1364–71.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H. Results from a 1-year, openlabel, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol. 2013;92(2):191–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, et al. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). Eur J Haematol. 2014;92(6):527–36.CrossRefPubMedGoogle Scholar
  35. 35.
    Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996;94:288–99.CrossRefPubMedGoogle Scholar
  36. 36.
    Leitch HA, Leger CS, Goodman TA, Wong KK, Wong DHC, Ramadan KM, et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin Leuk. 2008;2:205–11.CrossRefGoogle Scholar
  37. 37.
    Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDs patients? A multicenter study by the GFM. Leuk Res. 2010;34:864–70.CrossRefPubMedGoogle Scholar
  38. 38.
    Neukirchen J, Fox F, Kundgen A, Nachtkamp K, Strupp C, Haas R, et al. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Dusseldorf MDS registry. Leuk Res. 2012a;36(8):1067–70.CrossRefPubMedGoogle Scholar
  39. 39.
    Neukirchen J, Germing U, Fox F, Glaser S, Gattermann N. The impact of iron chelation therapy on clinical outcomes in real-world lower-risk patients with myelodysplastic syndromes (MDS): results from the Düsseldorf registry. Haematologica. 2012b;97(s1):144.Google Scholar
  40. 40.
    Komrokji RS, Al Ali NH, Padron E, Lancet JE, List A. Impact of iron chelation therapy on overall survival and AML transformation in lower-risk MDS patients treated at the Moffitt Cancer Center. Blood. 2011;118(21):2776.Google Scholar
  41. 41.
    Zeidan AM, Hendrick F, Friedman E, Gore SD, Baer MR, Sasane M, et al. Deferasirox is associated with reduced mortality risk in a Medicare population with myelodysplastic syndromes. Blood. 2012;120(21):426.Google Scholar
  42. 42.
    Delforge M, Selleslag D, Beguin Y, Triffet A, Mineur P, Theunissen K, et al. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. Leuk Res. 2014;38(5):557–63.CrossRefPubMedGoogle Scholar
  43. 43.
    Lyons RM, Marek BJ, Paley C, Esposito J, McNamara K, Garbo L, et al. Relationship between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndrome (MDS): registry analysis at 5 years. Blood. 2014;124(21):1350.Google Scholar
  44. 44.
    Remacha AF, Arrizabalaga B, Villegas A, Duran MS, Hermosin L, de Paz R, et al. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. Ann Hematol. 2015;94(5):779–87.CrossRefPubMedGoogle Scholar
  45. 45.
    Parmar A, Leitch HA, Wells RA, Nevill TJ, Zhu NY, Yee KWL, et al. Iron chelation is associated with improved survival adjusting for disease and patient related characteristics in low/int-1 risk MDS at the time of first transfusion dependence: A MDS-CAN study. Blood. 2015;126(23):1701.Google Scholar
  46. 46.
    Langemeijer S, de Swart L, Yu G, Smith A, Crouch S, Johnston T, et al. Impact of treatment with Iron chelators in lower-risk MDS patients participating in the European LeukemiaNet MDS (EUMDS) Registry. Blood. 2016;128(22):3186.Google Scholar
  47. 47.
    Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, et al. Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial. Am J Hematol. 2010;85(10):818–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, et al. Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial. Haematologica. 2011;96(7):1055–8.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557–66.CrossRefPubMedGoogle Scholar
  50. 50.
    Gattermann N, Finelli C, Della Porta M, Fenaux P, Ganser A, Guerci-Bresler A, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res. 2010;34:1143–50.CrossRefPubMedGoogle Scholar
  51. 51.
    Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122(17):2943–64.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Nolte F, Angelucci E, Breccia M, Gattermann N, Santini V, Vey N, et al. Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with deferasirox in transfusion dependent patients with myelodysplastic syndrome - emphasis on optimized dosing schedules and new formulations. Leuk Res. 2015;39(10):1028–33.CrossRefPubMedGoogle Scholar
  53. 53.
    Nolte F, Angelucci E, Beris P, Macwhannell A, Selleslag D, Schumann C, et al. Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox. Leuk Res. 2011;35(9):1131–5.CrossRefPubMedGoogle Scholar
  54. 54.
    Gattermann N, Schmid M, Della Porta M, Taylor K, Seymour JF, Habr D, et al. Efficacy and safety of deferasirox (Exjade) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: results from EPIC trial. Blood. 2008;112(11):633.Google Scholar
  55. 55.
    Schmid M, Cappellini MD, Porter JB, Greenberg PL, Lawniczek T, Glaser S, et al. Safety of Deferasirox (Exjade®) in myelodysplastic syndromes (MDS) and non-MDS patients with transfusional iron overload: a pooled analysis focusing on renal function. Blood. 2009;114(22):1768.Google Scholar
  56. 56.
    Gattermann N, Schmid M, Guerci-Bresler A, Della Porta M, Taylor K, Habr D, et al. Correlation between decreased serum ferritin and improved liver transaminases during Deferasirox (Exjade®) treatment in iron-overloaded patients with myelodysplastic syndromes. Blood. 2009;114(22):3803.Google Scholar
  57. 57.
    Taher AT, Origa R, Perrotta S, Kouraklis A, Ruffo GB, Kattamis A, et al. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or MDS: results of the randomized, phase II E.C.L.I.P.S.E. study. Blood. 2016;128(22):1285.Google Scholar
  58. 58.
    Taher AT, Origa R, Perrotta S, Kouraklis A, Ruffo GB, Kattamis A, et al. Improved patient-reported outcomes with a film-coated versus dispersible tablet formulation of deferasirox: results from the randomized, phase II E.C.L.I.P.S.E. Study. Blood. 2016;128(22):850.Google Scholar
  59. 59.
    McKay PJ, Murphy JA, Cameron S, Burnett AK, Campbell M, Tansey P, et al. Iron overload and liver dysfunction after allogeneic or autologous bonemarrow transplantation. Bone Marrow Transplant. 1996;17(1):63–6.PubMedGoogle Scholar
  60. 60.
    Strasser SI, Kowdley KV, Sale GE, McDonald GB. Iron overload in bone marrow transplant recipients. Bone Marrow Transplant. 1998;22(2):167–73.CrossRefPubMedGoogle Scholar
  61. 61.
    Strasser SI, Sullivan KM, Myerson D, Spurgeon CL, Storer B, Schoch HG, Murakami CS, McDonald GB. Cirrhosis of the liver in long-term marrow transplant survivors. Blood. 1999;93(10):3259–66.PubMedGoogle Scholar
  62. 62.
    Tomas JF, Pinilla I, Garcia-Buey ML, Garcia A, Figuera A, Gomez-Garcia deSoria VGG, et al. Long-term liver dysfunction after allogeneic bonemarrow transplantation: clinical features and course in 61 patients. Bone Marrow Transplant. 2000;26(6):649–55.CrossRefPubMedGoogle Scholar
  63. 63.
    Rose C, Ernst O, Hecquet B, Maboudou P, Renom P, Noel MP, et al. Quantification by magnetic resonance imaging and liver consequences of post-transfusional iron overload alone in long term survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Haematologica. 2007;92(6):850–3.CrossRefPubMedGoogle Scholar
  64. 64.
    Meyer SC, O’Meara A, Buser AS, Tichelli A, Passweg JR, Stern M. Prognostic impact of posttransplantation iron overload after allogeneic stemcell transplantation. Biol Blood Marrow Transplant. 2013;19(3):440–4.CrossRefPubMedGoogle Scholar
  65. 65.
    Armand P, Kim HT, Cutler C, Ho VT, Koreth J, Alyea EP, et al. Prognostic Impact of elevated pre-transplant serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;108:595.  https://doi.org/10.1181/blood-2006-10-054924.CrossRefGoogle Scholar
  66. 66.
    Platzbecker U, Bornhauser M, Germing U, Stumpf J, Scott BL, Kroger N, et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant. 2008;14(11):1217–25.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Alessandrino EP, Della Porta MG, Bacigalupo A, Malcovati L, Angelucci E, Van Lint MT. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica. 2010;95:476–84.CrossRefPubMedGoogle Scholar
  68. 68.
    Trottier BJ, Burns LJ, DeFor TE, Cooley S, Majhail NS. Association ofiron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. Blood. 2013;122(9):1678–84.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Armand P, Kim HT, Virtanen JM, Parkkola RK, Itala-Remes MA, Majhail NS, et al. Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. Biol Blood Marrow Transplant. 2014;20(8):1248–51.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Tachibana T, Takasaki H, Tanaka M, Maruta A, Hyo R, Ishigatsubo Y, et al. Serum ferritin and disease status at transplantation predict the outcome of allo-SCT in patients with AML or myelodysplastic syndrome. Bone Marrow Transplant. 2011;46(1):150–1.CrossRefPubMedGoogle Scholar
  71. 71.
    Naoum FA, Esposito BP, Ruiz LP, Ruiz MA, Tanaka PY, Sobreira JT, et al. Assessment of labile plasma iron in patients who undergo hematopoietic stem cell transplantation. Acta Haematol. 2014;131(4):222–6.CrossRefPubMedGoogle Scholar
  72. 72.
    Sakamoto S, Kawabata H, Kanda J, Uchiyama T, Mizumoto C, Kitano T, et al. High pretransplant hepcidin levels are associated with poor overall survival and delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation. Cancer Med. 2017;6(1):120–8.CrossRefPubMedGoogle Scholar
  73. 73.
    Bazuaye GN, Buser A, Gerull S, Tichelli A, Stern M. Prognostic impact of iron parameters in patients undergoing allo-SCT. Bone Marrow Transplant. 2012;47(1):60–4.CrossRefPubMedGoogle Scholar
  74. 74.
    Wermke M, Schmidt A, Middeke JM, Sockel K, von Bonin M, Schonefeldt C, et al. MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation. Clin Cancer Res. 2012;18(23):6460–8.CrossRefPubMedGoogle Scholar
  75. 75.
    Lee JW, Kang HJ, Kim EK, Kim H, Shin HY, Ahn HS. Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children. Bone Marrow Transplant. 2009;44(12):793–7.CrossRefPubMedGoogle Scholar
  76. 76.
    Sivgin S, Baldane S, Kaynar L, Kurnaz F, Pala C, Ozturk A, et al. Pretransplant serum ferritin level may be a predictive marker for outcomes in patients having undergone allogeneic hematopoietic stem cell transplantation. Neoplasma. 2012;59(2):183–90.CrossRefPubMedGoogle Scholar
  77. 77.
    Sivgin S, Baldane S, Kaynar L, Kurnaz F, Pala C, Sivgin H, et al. Pretransplant iron overload may be associated with increased risk of invasive fungal pneumonia (IFP) in patients that underwent allogeneic hematopoietic stem cell transplantation (alloHSCT). Transfus Apher Sci. 2013;48(1):103–8.CrossRefPubMedGoogle Scholar
  78. 78.
    Langemeijer S, De Swart L, Yu G, Smith A, Crouch S, Johnston T, Fenaux P, et al. Impact of treatment with iron chelators in lower-risk MDS patients participating in the European Leukemianet MDS (EUMDS) Registry. Blood. 2016;128:3186.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Hematology, Oncology and Clinical OncologyUniversity Hospital, Heinrich Heine University DüsseldorfDüsseldorfGermany
  2. 2.Service d’onco hématologie, Hôpital Saint Vincent de Paul, Université Catholique de LilleLilleFrance

Personalised recommendations